This company listing is no longer active
SOBI BTA Stock Overview
An integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 5/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Swedish Orphan Biovitrum AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 221.00 |
| 52 Week High | SEK 230.00 |
| 52 Week Low | SEK 213.00 |
| Beta | 0.38 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 0.91% |
Recent News & Updates
Recent updates
Shareholder Returns
| SOBI BTA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.5% | -0.3% | -2.2% |
| 1Y | n/a | 6.2% | 6.1% |
Return vs Industry: Insufficient data to determine how SOBI BTA performed against the Swedish Biotechs industry.
Return vs Market: Insufficient data to determine how SOBI BTA performed against the Swedish Market.
Price Volatility
| SOBI BTA volatility | |
|---|---|
| SOBI BTA Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in SE Market | 11.3% |
| 10% least volatile stocks in SE Market | 3.2% |
Stable Share Price: SOBI BTA has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SOBI BTA's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1939 | 1,793 | Guido Oelkers | www.sobi.com |
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and specialty care in Europe, North America, the Middle East, Asia, and Australia. It offers Alprolix for haemophilia B; Aspaveli®/Empaveli for the treatment of adult patients with paroxysmal nocturnal haemoglobinuria; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Zynlonta, an aggressive malignant disease; Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection. The company also provides other products, such as Akynzeo, Tegsedi, Jyseleca, Kepivance, Aloxi, and Waylivra.
Swedish Orphan Biovitrum AB (publ) Fundamentals Summary
| SOBI BTA fundamental statistics | |
|---|---|
| Market cap | SEK 74.27b |
| Earnings (TTM) | SEK 3.13b |
| Revenue (TTM) | SEK 20.10b |
23.8x
P/E Ratio3.7x
P/S RatioIs SOBI BTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SOBI BTA income statement (TTM) | |
|---|---|
| Revenue | SEK 20.10b |
| Cost of Revenue | SEK 4.70b |
| Gross Profit | SEK 15.40b |
| Other Expenses | SEK 12.27b |
| Earnings | SEK 3.13b |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
Oct 26, 2023
| Earnings per share (EPS) | 9.22 |
| Gross Margin | 76.61% |
| Net Profit Margin | 15.55% |
| Debt/Equity Ratio | 98.1% |
How did SOBI BTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/09/27 23:56 |
| End of Day Share Price | 2023/09/26 00:00 |
| Earnings | 2023/06/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Swedish Orphan Biovitrum AB (publ) is covered by 29 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alexander Lindström | ABG Sundal Collier |
| Rosie Turner | Barclays |
| Brian Balchin | Barclays |